Contrast-Enhanced Magnetic Resonance Imaging Based T1-Mapping and Extracellular Volume Fractions are Associated with Peripheral Artery Disease

Asem Fitian, MS, MD[a*], Michael C. Shieh, MD[b*], Olga A. Gimnich, PhD[a], Tatiana Belousova, MD[e], Addison A. Taylor, MD, PhD[b,d], Christie M. Ballantyne, MD[b,c], Jean Bismuth, MD[f], Dipan J. Shah, MD[e], Gerd Brunner, MS, PhD[a,b]

[a]Penn State Heart and Vascular Institute, Pennsylvania State University College of Medicine, Hershey, PA, USA
Sections of [b]Cardiovascular Research and [c]Cardiology, Department of Medicine, Baylor College of Medicine, Houston, TX, USA
[d]Michael E DeBakey VA Medical Center, Houston, Texas, USA
[e]Methodist DeBakey Heart and Vascular Center, Houston Methodist Hospital, Houston, Texas, USA
[f]Division of Vascular and Endovascular Surgery, Louisiana State University Health Sciences Center, New Orleans, LA

*These authors contributed equally.

Running Title: MRI-Based T1-Mapping and ECV in PAD

Address for correspondence:
Gerd Brunner, MS, PhD
500 University Drive H047
Hershey, PA 17033
Phone: +1 717-531-0003
Fax: +1 717-531-1792
E-mail: gbrunner@pennstatehealth.psu.edu

Keywords: peripheral artery disease; magnetic resonance imaging; T1 mapping; extracellular volume fraction; skeletal calf muscle

Abstract

Background: Extracellular volume fraction (ECV), measured with contrast-enhanced magnetic resonance imaging (CE-MRI), has been utilized to study myocardial fibrosis but its role in peripheral artery disease (PAD) remains unknown. We hypothesized that T1-mapping and ECV differ between PAD patients and matched-controls.

Methods and Results: A total of 37 individuals (18 PAD, 19 controls) underwent 3.0T CE-MRI at the mid-calf. T1-mapping was done before and after gadolinium contrast with a motion corrected Modified Look Locker Inversion Recovery (MOLLI) pulse sequence. T1 values were calculated with a 3-parameter Levenberg-Marquardt curve fitting algorithm. T1-maps were quantified in 5 calf muscle compartments (anterior [AM], lateral [LM], and deep posterior [DM] muscle groups; soleus [SM], and gastrocnemius [GM] muscles). Averaged peak blood pool T1 values were obtained from the posterior (PT) and anterior tibialis (AT); and peroneal artery (PE). PAD ECV was calculated for each muscle group. T1 values and ECV are heterogeneous across calf muscle compartments. Native peak T1 values of the AM, LM, and DM were significantly higher in PAD patients compared to controls (all $p<0.028$). ECV of the AM and SM were significantly higher in PAD patients compared to controls (AM: 26.4% (21.2, 31.6) vs. 17.3% (10.2, 25.1), $p=0.046$; SM: 22.7% (19.5, 27.8) vs. 13.8% (10.2, 19.1), $p=0.020$).

Conclusions: Native peak T1 values and ECV fractions of several calf muscle compartments are higher in PAD patients compared with matched-controls. These data suggest a potential utility of ECV to noninvasively determine skeletal muscle fibrosis in PAD.

Introduction

A natural outgrowth of the past decade's advancements in magnetic resonance imaging (MRI) and computed tomography (CT) has been the enhanced diagnostic accuracy of myriad ailments owing to the more robust processing power of state-of-the-art imaging modalities[1]. Notwithstanding the reproducibly more accurate detection of pathologies previously encumbered by limitations in imaging quality and efficiency, paradigm-changing advances in the disease monitoring and diagnosis realms—ones that detect diseases during their clinically silent stages rather than the conventional presentation when curative interventions are at best a long shot—continue to elude clinical fruition.

With advances in resolution and processing power occurring amid a deep learning and artificial intelligence (AI) revolution[2], the opportunity has emerged to, at still-more granular radiographic levels, define pathophysiologic underpinnings that not only more accurately delineate whether an anomaly is present but stratify the abnormality based on the most probable culprit central process or disease[3,4]. Such advancements in precision medicine and radiography have, for example, already been realized in the breast cancer diagnosis realm with significantly improved early detection of what would otherwise, in the setting of conventional surveillance modalities, prove clandestine tumors—and with superior efficacy capable of surmounting historically challenging clinical diagnostic conundrums[5,6].

To this end, radiomics-driven solutions are continually demonstrating game-changing potential in the effort to deliver early diagnostic and disease monitoring solutions to the cardiovascular disease arena down to previously unseen pathophysiologic levels. Notable advancements to this end include Bayesian networks that leverage data from stress echocardiography and CT angiography (CTA) to accurately predict future cardiovascular events such as myocardial infarction (MI) or death[7,8] a machine learning algorithm that outperforms

conventional diagnostic strategies for accurate detection of heart failure with preserved ejection fraction[9] among myriad other novel algorithms that show promise in the diagnosis of obstructive coronary stenoses[10], myocardial infarction[11], and peripheral vascular disease (PVD)[12]. Owing to the grim 10-year mortality rate facing patients with limb claudication that eclipses 50% when considering age and comorbid factors[13] and the increased rate of myocardial infarction, stroke, and cardiovascular death in patients with both symptomatic and asymptomatic peripheral artery disease (PAD)[14], it is imperative that one such paradigm change occurs in the surveillance for the earliest warning signs of limb ischemia.

One avenue of promise has emerged and stems from advances in quantifying the extracellular volume fraction (ECV) in the myocardium measured with contrast-enhanced magnetic resonance imaging (CE-MRI). The T1 relaxation time, a measure of how fast the nuclear spin magnetization equilibrates after a radiofrequency pulse in MRI, is an important tool for highlighting soft-tissue contrast. T1 times are specific to and span myriad pathologies, from fibrosis to fatty infiltration. Owing to the pathological underpinnings of fibrosis, arising from derailments in and expansion of extracellular matrix (ECM) remodeling[15], contrast-enhanced quantification of ECV has proven a useful means for detecting microscopic areas of ischemia, myocardial scarring, and perfusion[13,16].

Advances in cardiac MRI leverage pre- and post-contrast injection in T1 sequences to disclose precise, focal areas of pathology by measuring the rate of change of T1 relaxation relative to the degree of contrast pooling, with T1 times corresponding to pathologic states. For example, acute membrane rupture emblematic of acute MI and myocarditis allows aberrant infiltration of gadolinium contrast into myocytes, resulting in increased gadolinium concentration, prolonged T1 relaxation times, and the corresponding hyper-enhancement hallmark of acute MI. By the same token, in chronic MI, scarring prevails, with a corresponding expansion of the interstitium that leads to increased gadolinium concentration, hyper-enhancement, and correspondingly prolonged T1 times.

Previous works[17] [18] have demonstrated the potential reproducibility of T1 mapping beyond central cardiovascular to peripheral vascular pathophysiologic areas[19]. In this study, we investigated T1 times in PAD patients and matched controls. We hypothesized that differences in T1 relaxation times will be observed in PAD patients compared with appropriately matched controls.

Methods

The study was approved by the institutional review board and conducted in keeping with the Helsinki Declaration of 1973. Suitable patients from the Houston Methodist Hospital and the Michael E. DeBakey Veterans Affairs Medical Center in Houston, TX were identified using inclusion and exclusion criteria in the medical record. PAD patients and controls without PAD were recruited and matched on the basis of demographic and clinical characteristics. Standard of care continued uninterrupted throughout study subject participation in this observational imaging work. Patients with contraindications to MRI and those with an estimated glomerular filtration rate (eGFR) ≤40 mL/min/1.73.m^2 were excluded from this study.

Participants were positioned on the MRI table feet first in the supine position, and imaging was performed at the mid-calf level. Efforts to minimize motion artifact were employed using a bilateral leg coil employed during the imaging runtime. A gadolinium-based contrast agent was administered intravenously (gadopentetate dimeglumine [Magnevist, Bayer Healthcare, Whippany, New Jersey, USA at 0.2 mmol/kg, or gadobutrol [Gadavist, Bayer Healthcare, at 0.1 mmol/kg) with flow rates of 2-4 ml/sec proceeded by a 20 ml saline flush. MRI scans were saved in the DICOM format prior to rendering and further analysis. The arterial lumens of the anterior tibialis (AT), posterior tibial (PT), and peroneal artery (PE) were segmented and visualized as permitted by contrast enhancement using Sante DICOM Editor Version 3.0 (Santesoft, Nicosia, Cyprus).

The reproducibility and quality of the lumen frame analysis and interpretation were assessed through inter- and intraobserver reproducibility analyses. Cross-sectional leg muscle area (CSLMA) was measured using our previously described methodology.[18]

T1-mapping was done before and after gadolinium contrast administration with a motion-corrected Modified Look-Locker Inversion Recovery (MOLLI) pulse sequence. T1 values are reported in millisecond (ms) and were calculated with a 3-parameter Levenberg-Marquardt curve fitting algorithm. We reported the peak T1 values across the five calf muscle compartments including the anterior (AM), lateral (LM), and deep posterior (DM) muscle groups; soleus (SM), and gastrocnemius (GM) muscles. Averaged peak blood pool T1 values were obtained from the posterior (PT) and anterior tibialis (AT) and peroneal artery (PE). PAD ECV was calculated for each muscle group as (1-hematocrit in %) x [(1/T1m post) - (1/T1m pre)] / [(1/T1b post) - (1/T1b pre)], where T1m denotes the maximum T1 value of the respective muscle compartments and T1b the averaged peak arterial blood T1 value.

Variable normality was determined with the Shapiro-Wilk test. Group differences for categorical variables were analyzed with the Chi-square or Fisher exact test. Continuous variables were analyzed with an independent samples Student's t-test, and the Mann-Whitney-Wilcoxon test was used for non-normal variables. Associations between T1 times and markers of PAD were determined using linear regression. Sante DICOM Editor 3D was used for muscle compartment and lower extremity tracings, T1 extrapolation, and T1 mapping. Intra- and interclass correlations, performed on Stata with the ICC command using DICOM outputs from Sante, were conducted to assess variability in tracing and MRI data analysis between and within operators.

All statistical tests were two-sided, and a p-value <0.05 was used as the cutoff for statistically significant phenomena. The statistical analyses were performed with Stata Statistical Software: Release 13 (College Station, Texas, StataCorp LP).

Results

Patient Demographics

Patient demographic and clinical characteristics are shown in **Table 1**. Briefly, 66 individuals were enrolled, 5 participants did not complete baseline imaging, an additional 24 participants were excluded due to poor image quality or incomplete MRI exams. A total of 37 participants were included in the analysis (18 PAD patients, 19 matched-controls). Patients were age and gender matched, and there was an equivalent distribution of race among the respective groups. PAD patients compared to controls were more likely hypertensive and hyperlipidemic and had a higher rate of smoking history and prior lower extremity revascularization. As expected, PAD patients had a significantly lower ABI, shorter PWT, and were less likely to complete 6-minutes of treadmill walking compared with the matched-controls.

Intra-Observer Reproducibility

Intra-observer reproducibility was excellent for arterial tracings, and the delineations of the leg and the AM, LM, SM, and GM muscle compartments (**Table 2**).

Skeletal Muscle Native T1 Mapping

Native maximum T1 values averaged over the five skeletal muscle compartments (AM, LM, DM, SM, and GM) were significantly elevated in PAD patients compared with matched-controls (1902 (1877-1924) ms vs.1823 (1709-1883) ms, $p=0.005$; **Table 3**). Native maximum T1 values were significantly higher in PAD patients compared with controls for the AM, LM, DM (all $p<0.03$) but not for the SM and GM skeletal muscle compartments (Table 3). Native minimum T1 times were not different across the calf muscle compartments.

Skeletal Muscle ECV

Skeletal muscle ECV was significantly higher in PAD patients compared with controls for the AM (26.4 (21.2-31.5) % vs. 17.3 (10.2-25.1) %, p=0.046) and SM (22.7 (19.5-27.8) % vs. 13.8 (10.2-19.1) %, p=0.020), but not for the LM, DM, and GM.

Native maximum T1 and ECV

T1, ECV expression, cross-sectional muscle compartment area were compared among PAD patients and the control group (Table 3a). Maximum T1 values were then assessed in the AM, LM, DM, SM, and GM muscle compartments of the leg. The ECV fraction of muscle compartments was further evaluated. Finally, cross-sectional composite maximum and composite average T1 were evaluated for utility as an overall representative T1 measurement in PAD vs. controls. A significantly lower cross-sectional area of the AM and LM was observed in PAD patients versus controls. The composite averaged cross-sectional area of the lower extremity of PAD patients trended lower compared with the controls (p = 0.055). The composite maximum T1 for the entire cross-sectional area of the lower extremity was significantly higher in PAD patients versus that in the controls (p = 0.005). Notably, maximum T1 varied significantly among PAD patients versus controls. The minimum T1 values and mean T1 values averaged over all muscle compartments did not differ significantly between PAD patients and controls.

A subgroup analysis querying treadmill test completion among PAD patients with diabetes versus those without did not identify diabetes as a predictor of treadmill test noncompletion among PAD patients. Because of the elevated risk for PAD among patients with diabetes, we evaluated this association among several clinical parameters in a subgroup analysis involving diabetes-positive and diabetes-negative PAD patients. Table 3b delineates this analysis, revealing no significant difference in T1 or ECV between subgroups.

Linear Regression

To further assess the predictive capability of T1 and ECV fractions on the presence of PAD, we performed linear regression and assessed the association of T1 expression with selected parameters of clinical utility in PAD. The primary variables evaluated in relationship to T1 and ECV expression were resting ABI in the symptomatic leg, delta ABI, claudication onset time, peak walking time, body mass index (BMI), and eGFR. Regressions were performed with beta testing for PAD, controls, and pooled (PAD and controls). Pooled analyses were performed to assess T1 and ECV's inherent relationship with the listed parameters to demonstrate whether expression differences among groups could be ascribed to group classification rather than the phenomenon *per se*. Regarding T1 of muscle compartments, the maximum and mean T1 values were analyzed in relation to these parameters. Resting ABI in the pooled analyses was significantly associated with ECV in the DM and SM muscle groups. The remainder of the pooled analyses in Table 4a did not reveal a significant difference in these profiles among PAD patients and controls.

Linear Regression – Maximum and Mean ECV in muscle groups

Table 4c shows the linear regression results for maximum ECV of the muscle compartments. Regressions were performed to assess T1's potential correlation with the parameters of clinical interest. A significant negative correlation of the maximum ECV was observed in the AM in relationship to delta ABI of the symptomatic leg (p = 0.013, b = -0.621). No other significant findings were disclosed in this comparison. Pertaining to beta linear regression testing for controls versus PAD, ECV of the DM was negatively correlated with BMI (p = 0.001, b = 0.726). The soleus showed a significant positive relationship with maximum ECV with resting ABI (p = 0.034, b =0.403). Muscle group maximum ECV was otherwise unassociated with the indices evaluated across the five muscle compartments. No measurements were observed for claudication onset time in controls. In our pooled linear regression analysis for maximum ECV, a significant positive relationship was noted in the DM

with resting ABI (p = 0.041, b = 0.389). A negative association was observed for the DM with BMI (p = 0.001, b = -0.580).

Maximum and mean T1 associations with the selected clinical parameters was then assessed using linear regression. No significant findings were disclosed in the same analysis for mean T1 in the muscle respect to cases versus controls (Table 5a and 5b for maximum and mean T1, respectively). In PAD patients, we observed a significant negative correlation between resting ABI of the symptomatic leg and the maximum T1 of the DM (p = 0.020, b = -0.543). No significant associations were otherwise demonstrated compartments.

Maximum and mean T1 expression in the muscle compartments were then assessed for significant trends among the pooled cohort (Table 6a and 6b for maximum and mean, respectively). Resting ABI was significantly correlated with the mean T1 of the LM in the pooled study cohort. Otherwise, no notable trends of significance were noted in the pooled linear regression. As shown in Table 7, for the same analysis querying the significance of T1 in muscle compartments among controls, the maximum T1 of the DM was significantly and positively associated with delta ABI. The GM encompassed the other two significant findings in this analysis, showing significant and positive associations with delta ABI and BMI. No other significant results were found in the max or mean T1 in control beta testing.

Linear Regression – Maximum T1 Arteries

Maximum T1 values for the AT, PE, and PT arteries (Table 8) were then examined for correlation with the clinical parameters of PAD. Mean T1 values for these respective arteries and their relationship with the clinical parameters of PAD were also queried (Table 9). In PAD patients, a significant negative relationship was observed for the PT and claudication onset time (p = 0.013, b = -0.645). Pooled linear regression showed a significant positive relationship between the PT and delta ABI (p = 0.038, b = 0.357). No significant trends were observed in the

linear regression for controls. The composite T1 for all three arteries was then analyzed to evaluate the utility for a singular T1 value representative of the T1 of all three arteries to predict the presence of PVD. In this analysis (Table 10), the pooled linear regression showed a significant positive correlation with delta ABI (p = 0.044, b = 0.337). No other notable significant findings were observed.

Linear Regression – Composite Maximum Muscle Compartment T1

A composite maximum muscle compartment T1 was generated to evaluate the ability of this singular value to accurately stratify PAD patients from control subjects. For controls, delta ABI was significantly associated with the composite max T1 of all five muscle compartments (Table 11b). The pooled regression demonstrated a significant negative relationship between resting ABI and the averaged max T1 (Table 11c).

Linear Regression – Composite Average ECV

Similar to the composite index created for arterial and muscle compartment T1, we assessed the utility of a composite ECV representing the average ECV across all five muscle compartments to correlate with indices of interest for PAD (Table 12). In this analysis, however, no significant trends were observed.

Subgroup Analyses – Diabetic PAD Completers vs. Non-Completers

T1 was further tested for its capacity to stratify clinical subgroups within PAD. Among PAD patients, diabetics were identified, and beta testing with linear regression was performed. A significant relationship between non-completer status and diabetes was found for the SM in PAD. No other discernable trends were disclosed in this analysis.

Discussion

Novel radiographic markers that non-invasively identify early development of peripheral artery disease may help decrease clinical symptoms of this disease while improving patient quality of life and outcomes. The major finding of this work was a higher native peak T1 times in PAD patients versus matched controls, in keeping with prior works demonstrating a positive relationship between maximum T1 times and PAD. Higher maximum T1s were observed in muscle groups AM, LM, and DM in PAD patients compared to those in the controls. This is compatible with fibrosis and ischemia serving as potential pathophysiologic hallmarks of peripheral artery disease, consequently thus manifesting through elevated maximum T1s in PAD. Higher peak T1s were observed in the muscle groups AM, LM, and DM of PAD patients versus controls, and numerically higher trends were seen in the SM and GM compartments but did not meet the significant cutoff. These findings suggest ischemic muscle atrophy arising in PAD.

No association was seen in peak T1 times and the change in ABI (delta ABI), which could suggest that maximum T1 times are an independent marker of PAD. The benefit of this may lay in identifying perfusion derailments before the clinical manifestation of disease compelling ABI testing. This creates an opportunity for future prospective studies of T1 times and PAD presence and severity.

Prior works have demonstrated the value of ECV in coronary arterial disease and left ventricular dysfunction. Our findings identified a relationship between ECV and impairments in lower extremity perfusion. Atherosclerotic underpinnings that stem perfusion drive the ECV manifestations of ischemia seen on MRI, and this initial data suggests ECV may have potential as a radiographic marker of impaired lower extremity muscle perfusion.

Our study has limitations. The heterogeneity of findings, namely with regard to T1 relaxation times, limits the utility of T1 to serving as a potential surrogate marker of arterial perfusion. This, however, is an anticipated shortcoming and a result that agrees with those of other works, indicating the diminished utility of T1 relaxation as a specific radiographic marker of

direct arterial flow. Notwithstanding, it maintains promise as a non-invasive radiographic biomarker of pathologic hypoperfusion in lower extremity muscle compartments. Subjective parameters reported in this work such as smoking were self-reported factors. Additionally, the small sample size of this work precludes generalizability of its findings but does provide early groundwork that future works with larger patient cohorts can expound upon to further assess the role of native peak T1 and ECV in the study of PAD.

In conclusion, this study shows early promise of native peak T1 for stratifying PAD patients from matched controls, with increased native peak T1 times in lower extremity muscle groups. Given the need for non-invasive markers that can identify PAD in its pre-symptomatic state, future prospective studies with larger study cohorts are needed to better delineate the applicability of native peak T1 values to serve as non-invasive biomarkers of lower extremity hypoperfusion and PAD

Acknowledgements

The authors thank Ahsan Zil-E-Ali, MD, MPH for assistance with some components of the statistical analysis. The comments and guidance of Kelsey Caetano-Anolles, Ph.D., M.A. were instrumental for completion of this endeavor. Finally, the authors wish to thank the participants of this study for their dedication and commitment throughout the work.

Conflicts of Interest

The authors declare no conflicts of interest.

References

1. Al-Zaiti S, Besomi L, Bouzid Z, Faramand Z, Frisch S, Martin-Gill C, Gregg R, Saba S, Callaway C and Sejdić E. Machine learning-based prediction of acute coronary syndrome using only the pre-hospital 12-lead electrocardiogram. *Nature communications*. 2020;11:1-10.
2. Baessler B, Luecke C, Lurz J, Klingel K, Das A, von Roeder M, de Waha-Thiele S, Besler C, Rommel K-P and Maintz D. Cardiac MRI and texture analysis of myocardial T1 and T2 maps in myocarditis with acute versus chronic symptoms of heart failure. *Radiology*. 2019;292:608-617.
3. Forghani R, Savadjiev P, Chatterjee A, Muthukrishnan N, Reinhold C and Forghani B. Radiomics and artificial intelligence for biomarker and prediction model development in oncology. *Computational and structural biotechnology journal*. 2019;17:995.
4. Gimnich OA, Singh J, Bismuth J, Shah DJ and Brunner G. Magnetic resonance imaging based modeling of microvascular perfusion in patients with peripheral artery disease. *Journal of biomechanics*. 2019;93:147-158.
5. Harisinghani MG, O'Shea A and Weissleder R. Advances in clinical MRI technology. *Science Translational Medicine*. 2019;11:2591.
6. Jellis CL and Kwon DH. Myocardial T1 mapping: modalities and clinical applications. *Cardiovascular diagnosis and therapy*. 2014;4:126.
7. Ko ES and Morris EA. Abbreviated magnetic resonance imaging for breast cancer screening: concept, early results, and considerations. *Korean journal of radiology*. 2019;20:533-541.
8. Koçak B, Durmaz EŞ, Ateş E and Kılıçkesmez Ö. Radiomics with artificial intelligence: a practical guide for beginners. *Diagnostic and interventional radiology*. 2019;25:485.
9. Kuhl CK, Schrading S, Strobel K, Schild HH, Hilgers R-D and Bieling HB. Abbreviated breast magnetic resonance imaging (MRI): first postcontrast subtracted images and maximum-intensity projection—a novel approach to breast cancer screening with MRI. *Journal of Clinical Oncology*. 2014;32:2304-2310.
10. Lau L, Lo ZJ, Hong Q, Yong E, Zhang L, Chandrasekar S and Tan GWL. LEA 18. Systematic Review on the Use of Artificial Intelligence in Peripheral Vascular Diseases. *Journal of Vascular Surgery*. 2019;70:122.
11. Mueller T, Hinterreiter F, Luft C, Poelz W, Haltmayer M and Dieplinger B. Mortality rates and mortality predictors in patients with symptomatic peripheral artery disease stratified according to age and diabetes. *Journal of vascular surgery*. 2014;59:1291-1299.
12. Olin JW and Sealove BA. Peripheral artery disease: current insight into the disease and its diagnosis and management. *Mayo Clinic Proceedings*. 2010;85:678-692.
13. Ross EG, Shah NH, Dalman RL, Nead KT, Cooke JP and Leeper NJ. The use of machine learning for the identification of peripheral artery disease and future mortality risk. *Journal of vascular surgery*. 2016;64:1515-1522.
14. Sanchez-Martinez S, Duchateau N, Erdei T, Kunszt G, Aakhus S, Degiovanni A, Marino P, Carluccio E, Piella G and Fraser AG. Machine learning analysis of left ventricular function to characterize heart failure with preserved ejection fraction. *Circulation: cardiovascular imaging*. 2018;11:e007138.
15. Shieh MC, Belousova T, Taylor AA, Nambi V, Morrisett JD, Ballantyne CM, Bismuth J, Shah DJ and Brunner G. Contrast-Enhanced Magnetic Resonance Imaging Based T1-Mapping and Extracellular Volume Fractions are Associated With Peripheral Artery Disease. *Circulation*. 2017;136:A17267.
16. Than MP, Pickering JW, Sandoval Y, Shah ASV, Tsanas A, Apple FS, Blankenberg S, Cullen L, Mueller C and Neumann JT. Machine learning to predict the likelihood of acute myocardial infarction. *Circulation*. 2019;140:899-909.

17. Xiong G, Kola D, Heo R, Elmore K, Cho I and Min JK. Myocardial perfusion analysis in cardiac computed tomography angiographic images at rest. *Medical image analysis*. 2015;24:77-89.
18. Yang EY, Ghosn MG, Khan MA, Gramze NL, Brunner G, Nabi F, Nambi V, Nagueh SF, Nguyen DT and Graviss EA. Myocardial extracellular volume fraction adds prognostic information beyond myocardial replacement fibrosis. *Circulation: Cardiovascular Imaging*. 2019;12:e009535.
19. Zhu B, Liu JZ, Cauley SF, Rosen BR and Rosen MS. Image reconstruction by domain-transform manifold learning. *Nature*. 2018;555:487-492.

Table 1. Baseline patient characteristics.

Variables	PAD Patients (n=18)	Controls (n=19)	P-value
Age (years)	67.6 ± 7.19	65.4	0.43
Males, n (%)	11 (61.1)	11 (57.9)	0.84
Black race, n (%)	4 (22.2)	4 (21.1)	0.86
Body mass index (kg/m²)	27.1 ± 3.85	28.2 ± 5.20	0.48
Resting ABI	0.734 ± 0.22	1.16 ± 0.087	<0.0001
Delta ABI	0.179 ± 0.18	0.110 ± 0.097	0.16
History of smoking, n (%)	16 (88.9)	8 (42.1)	0.006
Diabetes, n (%)	7 (38.9)	3 (15.8)	0.11
Hypertension, n (%)	17 (94.4)	11 (57.8)	0.010
Hyperlipidemia, n (%)	17 (94.4)	11 (57.8)	0.010
Heart rate (bpm)	68.6 ± 15.9	63.7 ± 6.89	0.24
Hematocrit (%)	38.5 ± 5.73	41.2 ± 3.67	0.14
eGFR (ml/min/1.73m²)	71.7 ± 21.4	78.4 ± 18.0	0.36
Anticoagulation, n (%)	8 (44.4)	3 (16.7)	0.06
ACE inhibitor, n (%)	8 44.4)	5 (26.3)	0.25
Beta blocker, n (%)	9 (50.0)	7 (36.8)	0.42
Claudication onset time (sec)	112.6 ± 102.8	N/A	<0.0001
Peak walking time (sec)	298.2 ± 88.0	355.3 ± 20.6	0.009
Completed 6 min treadmill walking, n (%)	11 (64.7)	18 (94.7)	0.010
Cholesterol-lowering drug use, n (%)	15 (83.3)	8 (42.1)	0.010
Coronary artery disease, n (%)	8 (44.4)	4 (21.1)	0.13
Lower extremity revascularization history, n (%)	12 (66.7)	0 (0.0)	<0.0001
Family history of coronary heart disease, n (%)	11 (61.1)	8 (42.1)	0.25

Continuous variables are reported as mean ± standard deviation. PAD: peripheral artery disease; BMI: body mass index; eGFR: estimated glomerular filtration rate; ABI: ankle brachial index; ACE: angiotensin-converting enzyme. PAD patients: delta ABI, n=17; post-treadmill ABI, n=17; eGFR, n=14; claudication onset time, n=17; peak walking time, n=17; Completed 6 min treadmill, n=17. Matched-controls: heart rate, n=18; hematocrit, n=14; eGFR, n=18; anticoagulation, n=18; coronary artery disease, n=18. N/A in claudication onset time means that there were no claudication in the control group.

Table 2. Intra-observer variability as determined by the intra-class correlation (ICC) coefficient using a two-way model.

a)

	Intra-observer ICC for the anterior muscle group (right side)	Intra-observer ICC for the lateral muscle group (right side)	Intra-observer ICC for the deep posterior muscle group (right side)	Intra-observer ICC for the soleus muscle (right side)	Intra-observer ICC for the gastrocnemius muscle (right side)
Individual ICC (95% CI)	0.897 (0.794-0.951)	0.791 (0.594-0.897)	0.572 (0.274-0.771)	0.823 (0.658-0.913)	0.849 (0.707-0.926)
Average ICC (95% CI)	0.946 (0.885-0.975)	0.883 (0.746-0.946)	0.728 (0.430-0.871)	0.903 (0.794-0.954)	0.919 (0.828-0.962)

b)

	Intra-observer ICC for the anterior muscle group (left side)	Intra-observer ICC for the lateral muscle group (left side)	Intra-observer ICC for the deep posterior muscle group (left side)	Intra-observer ICC for the soleus muscle (left side)	Intra-observer ICC for the gastrocnemius muscle (left side)
Individual ICC (95% CI)	0.914 (0.825-0.959)	0.875 (0.750-0.939)	0.707 (0.463-0.851)	0.924 (0.841-0.964)	0.805 (0.629-0.903)
Average ICC (95% CI)	0.955 (0.904-0.979)	0.933 (0.857-0.969)	0.828 (0.633-0.920)	0.961 (0.914-0.982)	0.892 (0.772-0.949)

c)

	Intra-observer ICC for the anterior muscle group (bilateral average)	Intra-observer ICC for the lateral muscle group (bilateral average)	Intra-observer ICC for the deep posterior muscle group (bilateral average)	Intra-observer ICC for the soleus muscle (bilateral average)	Intra-observer ICC for the gastrocnemius muscle (bilateral average)
Individual ICC (95% CI)	0.912 (0.822-0.958)	0.890 (0.781-0.947)	0.647 (0.378-0.816)	0.901 (0.801-0.952)	0.842 (0.694-0.923)
Average ICC (95% CI)	0.954 (0.902-0.978)	0.942 (0.877-0.973)	0.786 (0.548-0.899)	0.948 (0.889-0.975)	0.914 (0.819-0.960)

d)

	Intra-observer ICC for the cross-sectional leg area (bilateral average)	Intra-observer ICC for the anterior tibialis artery (right side)	Intra-observer ICC for the anterior tibialis artery (left side)	Intra-observer ICC for the posterior tibialis artery (right side)	Intra-observer ICC for the posterior tibialis artery (left side)
Individual ICC (95% CI)	0.925 (0.847-0.964)	0.984 (0.984-0.985)	0.977 (0.975-0.978)	0.921 (0.918-0.924)	0.972 (0.970-0.975)
Average ICC (95% CI)	0.961 (0.917-0.982)	0.992 (0.992-0.992)	0.988 (0.987-0.989)	0.959 (0.957-0.960)	0.986 (0.985-0.987)

e)

	Intra-observer ICC for the peroneal artery (right side)	Intra-observer ICC for the peroneal artery (left side)
Individual ICC (95% CI)	0.876 (0.858-0.891)	0.914 (0.910-0.917)
Average ICC (95% CI)	0.934 (0.924-0.942)	0.955 (0.953-0.957)

ICC and confidence interval were calculated using a two-way model for 26 cases. ICC: intra-class correlation; CI: confidence interval.

Table 3a. MRI measurements.

Variables	PAD Patients (n=18)	Controls (n=19)	P-value
Maximum T1 of composite arteries (ms)	1729 (1679-1810)	1688 (1637-1756)	0.17
Cross-sectional area, anterior muscle group (mm²)	795 (678-980)	971 (802-1309)	0.045
Cross-sectional area, lateral muscle group (mm²)	454 (385-554)	597 (483-803)	0.007
Cross-sectional area, deep posterior muscle group (mm²)	677 (531-803)	624 (491-947)	1.00
Cross-sectional area, soleus muscle (mm²)	1459 (1235-1882)	1759 (1333-2322)	0.18
Cross-sectional area, gastrocnemius muscle (mm²)	1326 (1099-1800)	1649 (1204-2146)	0.11
Average cross-sectional area (mm²)	954 (828-1175)	1175 (954-1546)	0.055
Maximum T1, anterior muscle group (ms)	1835.5 (188)	1746 (163)	0.027
Maximum T1, lateral muscle group (ms)	1907 (65)	1755 (279)	0.002
Maximum T1, deep posterior muscle group (ms)	1917.5 (106)	1782 (296)	0.012
Maximum T1, soleus muscle (ms)	1930 (143)	1899 (164)	0.29
Maximum T1, gastrocnemius muscle (ms)	1945.5 (50)	1934 (160)	0.74
Minimum T1, anterior muscle group (ms)	878 (777-963)	878 (777-963)	0.53
Minimum T1, lateral muscle group (ms)	897 (818-955)	840 (718-926)	0.45
Minimum T1, deep posterior muscle group (ms)	729 (637-802)	712 (595-889)	0.87
Minimum T1, soleus muscle (ms)	728 (643-813)	823 (797-912)	0.024
Minimum T1, gastrocnemius muscle (ms)	730 (524-900)	651 (0-809)	0.55
Average cross-sectional maximum T1 (ms)	1902 (1877-1924)	1823 (1709-1883)	0.005
Average cross-sectional mean T1 (ms)	1218 (1143-1263)	1190 (1140-1258)	0.45
ECV, anterior muscle group (%)	26.4 (21.2-31.5)	17.3 (10.2-25.1)	0.046
ECV, lateral muscle group (%)	21.7 (15.1-31.2)	24.7 (19.6-38.5)	0.43
ECV, deep posterior muscle group (%)	29.0 (22.5-36.1)	24.1 (16.5-31.0)	0.19
ECV, soleus muscle (%)	22.7 (19.5-27.8)	13.8 (10.2-19.1)	0.020
ECV, gastrocnemius muscle (%)	21.8 (15.1-26.5)	16.8 (13.3-23.6)	0.38
ECV, averaged over 5 muscle compartments (%)	22.9 (21.0-27.5)	24.5 (20.7-28.0)	0.68

Values are reported as median (interquartile range, IQR); PAD: peripheral artery disease; ms: milliseconds; ECV: extracellular volume fraction. Composite denotes the T1 average for the peroneal, posterior tibialis, and anterior tibialis arteries combined. Average cross-sectional: average T1 times over all five muscle groups. ECV in controls (n=12), ECV in PAD patients (n=16).

Table 3b. MRI measurements in diabetic vs. non-diabetic patients with peripheral artery disease.

Variables	Diabetic PAD Patients (n=7)	Non-Diabetic PAD Patients (n=11)	P-value
Maximum T1, anterior muscle group (ms)	1955 ± 204	1811 ± 138	0.15
Maximum T1, lateral muscle group (ms)	1897 ± 134	1921 ± 136	0.89
Maximum T1, deep posterior muscle group (ms)	1903 ± 48	1916 ± 80	0.19
Maximum T1, soleus muscle (ms)	1980 ± 250	1917 ± 127	0.26
Maximum T1, gastrocnemius muscle (ms)	1947 ± 125	1932 ± 50	0.62
Average cross-sectional, maximum T1 (ms)	1924 ± 83	1911 ± 39	0.14
Average cross-sectional, mean T1 (ms)	1270 ± 138	1227 ± 84	0.49
ECV, anterior muscle group (%)	23.2 ± 13	28.1 ± 10	0.33
ECV, deep posterior muscle group (%)	28.5 ± 20	29.0 ± 10	0.91
ECV, lateral muscle group (%)	21.3 ± 16	23.1 ± 16	0.66
ECV, soleus muscle (%)	19.5 ± 9.1	24.6 ± 7.7	0.13
ECV, gastrocnemius muscle (%)	16.8 ± 14.9	22.7 ± 9.1	0.33
ECV, average cross-sectional (%)	26.8 ± 8.12	22.8 ± 2.5	0.33

PAD: peripheral artery disease; ms: milliseconds; ECV: extracellular volume fraction. Average cross-sectional: average T1 times or ECV over all five muscle groups. Diabetic PAD patients (n=6), Non-diabetic PAD patients (n=10).

Table 4a. Pooled linear regression analyses for maximum ECV enhancement of muscle compartments with clinical measures.

	Independent Variables	n	β	Standard Error	R^2	Adjusted r^2	P-value
ECV AM (%)	Resting ABI	28	0.243	9.086	0.06	0.02	0.21
	Δ ABI	27	-0.213	-23.030	0.05	0.05	0.28
	Claudication onset time (sec)	27	0.150	0.018	0.02	-0.02	0.46
	Peak walking time (sec)	27	-0.201	-0.035	0.04	0.002	0.31
	Body mass index (kg/m²)	27	-0.216	-0.501	0.05	0.01	0.27
	eGFR (ml/min/1.73m²)	27	0.079	0.041	0.006	-0.04	0.72
ECV LM (%)	Resting ABI	28	0.244	9.086	0.06	0.02	0.21
	Δ ABI	27	-0.213	-23.034	0.05	0.01	0.28
	Claudication onset time (sec)	27	-0.081	-0.009	0.01	-0.03	0.69
	Peak walking time (sec)	27	0.146	0.023	0.02	-0.02	0.47
	Body mass index (kg/m²)	28	-0.052	-0.116	0.003	-0.04	0.79
	eGFR (ml/min/1.73m²)	23	-0.122	-0.064	0.02	-0.03	0.58
ECV DM (%)	Resting ABI	28	0.389	3.197	0.15	0.12	0.041
	Δ ABI	27	0.080	4.055	0.01	-0.03	0.69
	Claudication onset time (sec)	27	0.135	0.013	0.02	-0.02	0.50
	Peak walking time (sec)	27	-0.192	-0.027	0.04	-0.002	0.34
	Body mass index (kg/m²)	28	-0.580	-1.120	0.34	0.31	0.001
	eGFR (ml/min/1.73m²)	23	0.373	0.176	0.14	0.10	0.08
ECV SM (%)	Resting ABI	28	0.403	1.580	0.16	0.13	0.034
	Δ ABI	27	-0.093	-9.920	0.01	-0.03	0.64
	Claudication onset time (sec)	27	0.226	0.024	0.05	0.01	0.26
	Peak walking time (sec)	27	0.029	0.004	0.001	-0.04	0.89
	Body mass index (kg/m²)	28	-0.247	0.394	0.06	0.02	0.21
	eGFR (ml/min/1.73m²)	23	0.244	0.128	0.06	0.01	0.26
ECV GM (%)	Resting ABI	28	0.104	0.669	0.01	-0.03	0.60
	Δ ABI	27	0.140	5.410	0.02	-0.02	0.49
	Claudication onset time (sec)	27	0.112	0.015	0.01	-0.03	0.58
	Peak walking time (sec)	27	-0.022	-0.002	0.001	-0.04	0.91
	Body mass index (kg/m²)	28	-0.247	-0.511	0.06	0.02	0.21
	eGFR (ml/min/1.73m²)	23	-0.020	0.007	0.00	-0.05	0.93

ECV: extracellular volume fraction; ABI: ankle-brachial index; Δ ABI: Delta ABI; eGFR: estimated glomerular filtration rate. n: Number of study subjects. AM: Anterior muscle group. LM: Lateral muscle group. DM: Deep muscle group. SM: Soleus muscle. GM: Gastrocnemius muscle.

Table 4b. Linear regression for maximum ECV enhancement of muscle compartments with clinical measures (control).

	Independent Variables	*n*	β	Standard Error	R^2	Adjusted r^2	*p*-value
ECV AM (%)	Resting ABI	12	0.105	15.340	0.01	-0.09	0.74
	Δ ABI	12	0.463	327.50	0.22	0.14	0.13
	Claudication onset time (sec)	--	--	--	--	--	--
	Peak walking time (sec)	12	-0.326	123.690	0.11	0.02	0.30
	Body mass index (kg/m²)	12	0.023	0.038	0.001	-0.10	0.94
	eGFR (ml/min/1.73m²)	11	-0.120	-0.061	0.01	-0.09	0.73
ECV LM (%)	Resting ABI	12	0.334	42.450	0.11	0.02	0.29
	Δ ABI	12	-0.246	-24.580	0.06	-0.03	0.44
	Claudication onset time (sec)	--	--	--	--	--	--
	Peak walking time (sec)	12	-0.326	-0.129	0.06	-0.03	0.44
	Body mass index (kg/m²)	12	0.023	0.038	0.001	-0.1	0.94
	eGFR (ml/min/1.73m²)	11	-0.560	-0.275	0.31	0.24	0.07
ECV DM (%)	Resting ABI	12	0.134	17.270	0.02	-0.08	0.68
	Δ ABI	12	0.041	1.980	0.002	-0.10	0.90
	Claudication onset time (sec)	--	--	--	--	--	--
	Peak walking time (sec)	12	-0.350	-0.141	0.12	0.03	0.26
	Body mass index (kg/m²)	12	-0.726	-1.190	0.53	0.40	0.008
	eGFR (ml/min/1.73m²)	11	0.459	0.224	0.21	0.12	0.16
ECV SM (%)	Resting ABI	12	0.0581	7.413	0.003	-0.09	0.86
	Δ ABI	12	0.066	6.617	0.004	-0.09	0.84
	Claudication onset time (sec)	--	--	--	--	--	--
	Peak walking time (sec)	12	0.045	0.017	0.004	-0.09	0.07
	Body mass index (kg/m²)	12	-0.610	0.476	0.14	0.05	0.23
	eGFR (ml/min/1.73m²)	11	0.173	0.087	0.03	-0.08	0.61
ECV GM (%)	Resting ABI	12	0.066	7.210	0.004	-0.09	0.84
	Δ ABI	12	0.075	6.440	0.006	-0.09	0.82
	Claudication onset time (sec)	--	--	--	--	--	--
	Peak walking time (sec)	12	0.095	0.032	0.009	-0.09	0.77
	Body mass index (kg/m²)	12	0.335	0.464	0.11	0.02	0.29
	eGFR (ml/min/1.73m²)	11	-0.183	-0.076	0.03	-0.07	0.59

ECV: extracellular volume fraction; ABI: ankle-brachial index; Δ ABI: difference between resting ABI and post-treadmill walking ABI; eGFR: estimated glomerular filtration rate**.** AM: Anterior muscle group. LM: Lateral muscle group. DM: Deep muscle group. SM: Soleus muscle. GM: Gastrocnemius muscle.

Table 4c. Linear regression for maximum ECV enhancement of muscle compartments with clinical measures (PAD cases).

	Independent Variables	*n*	β	Standard Error	R^2	Adjusted r^2	*p*-value
ECV AM (%)	Resting ABI	16	0.332	0.194	0.15	0.07	0.21
	Δ ABI	15	-0.621	-66.7	0.39	0.34	0.013
	Claudication onset time (sec)	15	0.039	0.004	0.002	-0.07	0.89
	Peak walking time (sec)	15	-0.065	-0.008	0.004	-0.07	0.82
	Body mass index (kg/m²)	16	0.173	-0.480	0.03	-0.04	0.52
	eGFR (ml/min/1.73m²)	12	0.394	0.194	0.15	0.07	0.21
ECV LM (%)	Resting ABI	16	0.115	5.480	0.01	-0.05	0.67
	Δ ABI	15	-0.143	-16.5	0.02	-0.05	0.61
	Claudication onset time (sec)	15	0.039	0.004	0.002	-0.05	0.89
	Peak walking time (sec)	15	0.195	0.026	0.04	-0.04	0.49
	Body mass index (kg/m²)	16	-0.242	-0.711	0.06	0.01	0.37
	eGFR (ml/min/1.73m²)	12	0.442	0.124	0.19	0.11	0.15
ECV DM (%)	Resting ABI	16	0.332	12.5	0.11	0.05	0.21
	Δ ABI	15	-0.134	-12.0	0.02	-0.06	0.63
	Claudication onset time (sec)	15	-0.109	-0.009	0.01	-0.06	0.70
	Peak walking time (sec)	15	-0.033	-0.003	0.001	-0.08	0.91
	Body mass index (kg/m²)	16	-0.326	-0.758	0.10	0.04	0.22
	eGFR (ml/min/1.73m²)	12	0.442	0.193	0.19	0.12	0.15
ECV SM (%)	Resting ABI	16	0.334	13.750	0.11	0.05	0.21
	Δ ABI	15	-0.407	-40.4	0.16	0.10	0.13
	Claudication onset time (sec)	15	-0.020	-0.002	0.00	-0.07	0.94
	Peak walking time (sec)	15	0.269	0.031	0.07	0.001	0.33
	Body mass index (kg/m²)	16	0.046	0.117	0.06	-0.01	0.87
	eGFR (ml/min/1.73m²)	12	0.474	0.238	0.23	0.15	0.12
ECV GM (%)	Resting ABI	16	0.330	9.650	0.11	0.04	0.21
	Δ ABI	15	-0.260	-17.1	0.07	-0.004	0.35
	Claudication onset time (sec)	15	-0.009	-0.001	0.00	-0.08	0.97
	Peak walking time (sec)	15	0.051	0.004	0.003	-0.07	0.86
	Body mass index (kg/m²)	16	-0.059	-0.106	0.003	-0.07	0.83
	eGFR (ml/min/1.73m²)	12	0.257	0.087	0.11	0.04	0.42

ECV: extracellular volume fraction; ABI: ankle-brachial index; Δ ABI: difference between resting ABI and post-treadmill walking ABI; eGFR: estimated glomerular filtration rate**.** AM: Anterior muscle group. LM: Lateral muscle group. DM: Deep muscle group. SM: Soleus muscle. GM: Gastrocnemius muscle.

Table 5a. Association of maximum T1 values for muscle compartments with indicated parameters by linear regression (PAD).

	Independent Variables	*n*	β	Standard Error	R^2	Adjusted r^2	*p*-value
Max T1 AM (ms)	Resting ABI	18	-0.457	-165.7	0.21	0.16	0.06
	Δ ABI	17	-0.069	-31.1	0.005	-0.06	0.79
	Claudication onset time (sec)	17	-0.086	-0.068	0.007	-0.06	0.74
	Peak walking time (sec)	17	-0.084	-0.077	0.007	-0.06	0.75
	Body mass index (kg/m²)	18	0.090	1.85	0.008	-0.05	0.72
	eGFR (ml/min/1.73m²)	13	-0.076	-0.304	0.006	-0.09	0.81
Max T1 LM (ms)	Resting ABI	18	0.098	133.1	0.01	-0.05	0.70
	Δ ABI	17	0.061	76.7	0.004	-0.06	0.82
	Claudication onset time (sec)	17	0.096	0.095	0.01	-0.06	0.71
	Peak walking time (sec)	17	-0.170	-0.441	0.03	-0.04	0.51
	Body mass index (kg/m²)	18	0.012	0.943	0.00	-0.06	0.96
	eGFR (ml/min/1.73m²)	13	-0.225	-0.966	0.05	-0.04	0.46
Max T1 DM (ms)	Resting ABI	18	-0.543	-646.8	0.30	0.25	0.02
	Δ ABI	17	0.291	427.7	0.09	0.02	0.26
	Claudication onset time (sec)	17	-0.113	-0.082	0.01	-0.05	0.67
	Peak walking time (sec)	17	-0.033	-0.029	0.001	-0.07	0.90
	Body mass index (kg/m²)	18	-0.334	-6.810	0.11	0.06	0.18
	eGFR (ml/min/1.73m²)	13	-0.398	-5.480	0.16	0.08	0.18
Max T1 SM (ms)	Resting ABI	18	-0.135	-64.80	0.02	-0.04	0.59
	Δ ABI	17	0.172	100.3	0.03	-0.04	0.51
	Claudication onset time (sec)	17	0.085	0.067	0.01	-0.06	0.75
	Peak walking time (sec)	17	-0.350	-0.418	0.12	0.06	0.17
	Body mass index (kg/m²)	18	0.226	6.15	0.05	-0.01	0.37
	eGFR (ml/min/1.73m²)	13	0.185	1.010	0.03	-0.05	0.54
Max T1 GM (ms)	Resting ABI	18	0.029	10.5	.001	-0.06	0.91
	Δ ABI	17	-0.124	-53.7	0.02	-0.05	0.64
	Claudication onset time (sec)	17	-0.156	-0.119	0.03	-0.04	0.55
	Peak walking time (sec)	17	-0.140	-0.125	0.02	-0.05	0.59
	Body mass index (kg/m²)	18	0.147	2.99	0.02	-0.04	0.56
	eGFR (ml/min/1.73m²)	13	0.325	1.390	0.11	0.02	0.28

ABI: ankle-brachial index; Δ ABI: difference between resting ABI and post-treadmill walking ABI; eGFR: estimated glomerular filtration rate; ms: milliseconds**.** Maximum T1, the dependent variable tested, corresponding to the maximum measured T1 relaxation time of the referenced anatomic area. AM: Anterior muscle group. LM: Lateral muscle group. DM: Deep muscle group. SM: Soleus muscle. GM: Gastrocnemius muscle.

Table 5b. Association of mean T1 values for muscle compartments with indicated parameters by linear regression (PAD).

	Independent Variables	*n*	β	Standard Error	R^2	Adjusted r^2	*p*-value
Mean T1 AM (ms)	Resting ABI	18	-0.457	-165.7	0.21	0.16	0.06
	Δ ABI	17	-0.069	-31.1	0.005	-0.06	0.79
	Claudication onset time (sec)	17	-0.086	-0.069	0.007	-0.06	0.74
	Peak walking time (sec)	17	-0.084	-0.077	0.007	-0.06	0.75
	Body mass index (kg/m²)	18	0.090	1.85	0.008	-0.05	0.72
	eGFR (ml/min/1.73m²)	13	-0.076	-0.304	0.006	-0.09	0.81
Mean T1 LM (ms)	Resting ABI	18	-0.272	-123.3	0.07	0.02	0.27
	Δ ABI	17	-0.323	-181.0	0.10	0.04	0.21
	Claudication onset time (sec)	17	0.096	0.095	0.01	-0.06	0.71
	Peak walking time (sec)	17	0.163	0.188	0.03	-0.04	0.53
	Body mass index (kg/m²)	17	0.051	1.32	0.00	-0.06	0.84
	eGFR (ml/min/1.73m²)	13	-0.225	-0.966	0.05	-0.04	0.46
Mean T1 DM (ms)	Resting ABI	18	0.004	1.30	0.00	-0.06	0.99
	Δ ABI	17	-0.435	-180.5	0.19	0.14	0.08
	Claudication onset time (sec)	17	-0.113	-0.082	0.01	-0.05	0.67
	Peak walking time (sec)	17	-0.033	-0.029	0.001	-0.07	0.90
	Body mass index (kg/m²)	18	-0.334	-6.81	0.11	0.06	0.18
	eGFR (ml/min/1.73m²)	13	-0.034	-0.136	0.001	-0.09	0.91
Mean T1 SM (ms)	Resting ABI	18	-0.212	-79.0	0.05	-0.05	0.40
	Δ ABI	17	0.028	12.7	0.001	-0.07	0.91
	Claudication onset time (sec)	17	0.085	0.067	0.007	-0.06	0.75
	Peak walking time (sec)	17	-0.158	-0.145	0.03	-0.04	0.54
	Body mass index (kg/m²)	18	0.084	1.78	0.007	-0.06	0.74
	eGFR (ml/min/1.73m²)	13	0.227	0.974	0.05	-0.04	0.46
Mean T1 GM (ms)	Resting ABI	18	-0.356	-128.5	0.13	0.07	0.15
	Δ ABI	17	-0.122	-49.0	0.02	-0.05	0.64
	Claudication onset time (sec)	17	-0.089	-208.7	0.08	0.02	0.27
	Peak walking time (sec)	17	0.164	0.135	0.02	-0.04	0.53
	Body mass index (kg/m²)	18	0.068	1.40	0.005	-0.06	0.79
	eGFR (ml/min/1.73m²)	13	-0.059	-0.231	0.003	-0.09	0.85

ABI: ankle-brachial index; Δ ABI: difference between resting ABI and post-treadmill walking ABI; eGFR: estimated glomerular filtration rate; ms: milliseconds**.** Maximum T1, the dependent variable tested, corresponding to the maximum measured T1 relaxation time of the referenced anatomic area. AM: Anterior muscle group. LM: Lateral muscle group. DM: Deep muscle group. SM: Soleus muscle. GM: Gastrocnemius muscle.

Table 6a. Association of maximum T1 values for muscle compartments in the pooled cohort with indicated parameters by linear regression.

	Independent Variables	*n*	β	Standard Error	R^2	Adjusted r^2	*p*-value
Max T1 AM (ms)	Resting ABI	37	-0.276	-73.6	0.08	0.05	0.10
	Δ ABI	36	0.201	237.4	0.04	0.01	0.24
	Claudication onset time (sec)	36	0.083	0.159	0.01	-0.02	0.63
	Peak walking time (sec)	36	-0.354	-0.893	0.13	0.10	0.03
	Body mass index (kg/m²)	37	0.153	5.79	0.02	-0.01	0.37
	eGFR (ml/min/1.73m²)	31	-0.152	-1.33	0.02	-0.01	0.42
Max T1 LM (ms)	Resting ABI	37	-0.359	-120.2	0.13	0.10	0.029
	Δ ABI	36	0.277	258.7	0.08	0.05	0.10
	Claudication onset time (sec)	36	0.344	0.517	0.12	0.09	0.040
	Peak walking time (sec)	36	-0.141	-0.281	0.02	-0.01	0.41
	Body mass index (kg/m²)	37	0.166	4.87	0.03	0.00	0.33
	eGFR (ml/min/1.73m²)	31	0.049	0.347	0.002	-0.03	0.79
Max T1 DM (ms)	Resting ABI	37	-0.102	-26.2	0.01	-0.02	0.55
	Δ ABI	36	0.216	240.8	0.05	0.02	0.21
	Claudication onset time (sec)	36	-0.026	-0.046	0.00	-0.03	0.88
	Peak walking time (sec)	36	-0.199	-0.472	0.04	0.01	0.25
	Body mass index (kg/m²)	37	0.110	3.85	0.01	-0.02	0.52
	eGFR (ml/min/1.73m²)	31	0.011	0.093	0.00	-0.03	0.95
Max T1 SM (ms)	Resting ABI	37	-0.141	-59.9	0.02	-0.01	0.41
	Δ ABI	36	0.192	153.0	0.04	0.01	0.26
	Claudication onset time (sec)	36	0.122	0.156	0.02	-0.01	0.48
	Peak walking time (sec)	36	-0.233	-0.395	0.05	0.03	0.17
	Body mass index (kg/m²)	37	-0.071	-1.78	0.01	-0.02	0.68
	eGFR (ml/min/1.73m²)	31	-0.144	0.902	0.02	-0.01	0.44
Max T1 GM (ms)	Resting ABI	37	-0.199	-75.8	0.04	0.01	0.24
	Δ ABI	36	0.185	131.7	0.03	0.01	0.28
	Claudication onset time (sec)	36	0.024	0.027	0.001	-0.03	0.89
	Peak walking time (sec)	36	-0.091	-0.139	0.01	-0.02	0.60
	Body mass index (kg/m²)	37	0.353	7.94	0.12	0.10	0.032
	eGFR (ml/min/1.73m²)	31	0.131	0.672	0.02	-0.02	0.48

ABI: ankle-brachial index; Δ ABI: difference between resting ABI and post-treadmill walking ABI; eGFR: estimated glomerular filtration rate; ms: milliseconds**.** Maximum T1, the dependent variable tested, corresponding to the maximum measured T1 relaxation time of the referenced anatomic area. AM: Anterior muscle group. LM: Lateral muscle group. DM: Deep muscle group. SM: Soleus muscle. GM: Gastrocnemius muscle.

Table 6b. Association of mean T1 values for muscle compartments in the pooled cohort with indicated parameters by linear regression.

	Independent Variables	*n*	β	Standard Error	R^2	Adjusted r^2	*P*-value
Mean T1 AM (ms)	Resting ABI	37	-0.275	-73.6	0.08	0.05	0.10
	Δ ABI	36	-0.019	-9.88	<0.001	-0.03	0.91
	Claudication onset time (sec)	36	0.010	0.008	<0.001	-0.03	0.96
	Peak walking time (sec)	36	-0.109	-0.117	0.01	-0.02	0.53
	Body mass index (kg/m²)	37	0.123	1.93	0.02	-0.01	0.47
	eGFR (ml/min/1.73m²)	31	-0.105	-0.404	0.01	-0.02	0.57
Mean T1 LM (ms)	Resting ABI	37	-0.359	-120.2	0.13	0.10	0.029
	Δ ABI	36	-0.043	-27.3	0.002	-0.03	0.80
	Claudication onset time (sec)	36	0.228	0.233	0.05	0.02	0.18
	Peak walking time (sec)	36	-0.006	-0.008	<0.001	-0.03	0.97
	Body mass index (kg/m²)	37	-0.084	-1.67	0.007	-0.02	0.62
	eGFR (ml/min/1.73m²)	31	-0.095	-0.423	0.009	-0.03	0.61
Mean T1 DM (ms)	Resting ABI	37	-0.102	-26.2	0.01	-0.02	0.55
	Δ ABI	36	-0.111	-52.0	0.01	-0.02	0.52
	Claudication onset time (sec)	36	0.017	0.013	<0.001	-0.03	0.92
	Peak walking time (sec)	36	-0.093	-0.092	0.009	-0.02	0.59
	Body mass index (kg/m²)	37	-0.120	-1.82	0.01	-0.01	0.48
	eGFR (ml/min/1.73m²)	31	-0.052	-0.193	0.003	-0.03	0.78
Mean T1 SM (ms)	Resting ABI	37	-0.151	-46.4	0.02	-0.005	0.37
	Δ ABI	36	0.122	70.0	0.02	-0.008	0.40
	Claudication onset time (sec)	36	0.105	0.097	0.01	-0.012	0.54
	Peak walking time (sec)	36	-0.143	-0.175	0.02	-0.008	0.40
	Body mass index (kg/m²)	37	-0.095	-1.71	0.01	-0.02	0.58
	eGFR (ml/min/1.73m²)	31	0.155	0.701	0.02	-0.01	0.41
Mean T1 GM (ms)	Resting ABI	37	-0.073	-24.5	0.01	-0.02	0.67
	Δ ABI	36	-0.007	-4.63	<0.001	-0.03	0.97
	Claudication onset time (sec)	36	-0.058	-0.057	0.003	-0.03	0.74
	Peak walking time (sec)	36	0.087	0.113	0.008	-0.02	0.61
	Body mass index (kg/m²)	37	0.122	2.43	0.01	-0.01	0.47
	eGFR (ml/min/1.73m²)	31	0.024	0.116	0.001	-0.03	0.90

ABI: ankle-brachial index; Δ ABI: difference between resting ABI and post-treadmill walking ABI; eGFR: estimated glomerular filtration rate**.** AM: Anterior muscle group. LM: Lateral muscle group. DM: Deep muscle group. SM: Soleus muscle. GM: Gastrocnemius muscle.

Table 7a. Association of maximum T1 values for muscle compartments in controls with indicated parameters by linear regression.

	Independent Variables	*n*	β	Standard Error	R^2	Adjusted r^2	*p*-value
Max T1 AM (ms)	Resting ABI	19	0.230	439.8	0.05	-0.003	0.34
	Δ ABI	19	0.013	22.3	0.00	-0.06	0.96
	Claudication onset time (sec)	--	--	--	--	--	--
	Peak walking time (sec)	19	0.101	0.822	0.01	-0.05	0.68
	Body mass index (kg/m²)	19	0.167	5.37	0.03	-0.03	0.49
	eGFR (ml/min/1.73m²)	18	-0.279	-2.66	0.08	0.02	0.26
Max T1 LM (ms)	Resting ABI	19	-0.228	-381.9	0.05	-0.004	0.35
	Δ ABI	19	0.454	688.9	0.21	0.16	0.05
	Claudication onset time (sec)	--	--	--	--	--	--
	Peak walking time (sec)	19	0.145	1.03	0.02	-0.04	0.55
	Body mass index (kg/m²)	19	0.304	8.60	0.09	0.04	0.21
	eGFR (ml/min/1.73m²)	18	0.234	1.91	0.06	-0.004	0.35
Max T1 DM (ms)	Resting ABI	19	-0.055	-106.3	0.003	-0.06	0.82
	Δ ABI	19	0.570	1006.3	0.33	0.29	0.011
	Claudication onset time (sec)	--	--	--	--	--	--
	Peak walking time (sec)	19	0.185	1.53	0.03	-0.02	0.45
	Body mass index (kg/m²)	19	0.205	6.72	0.04	-0.01	0.40
	eGFR (ml/min/1.73m²)	18	-0.012	-0.111	0.00	-0.06	0.96
Max T1 SM (ms)	Resting ABI	19	0.172	244.0	0.03	-0.03	0.48
	Δ ABI	19	0.192	246.7	0.04	-0.02	0.43
	Claudication onset time (sec)	--	--	--	--	--	--
	Peak walking time (sec)	19	0.071	0.426	0.005	-0.05	0.77
	Body mass index (kg/m²)	19	-0.217	5.20	0.05	-0.01	0.37
	eGFR (ml/min/1.73m²)	18	0.151	1.07	0.02	-0.04	0.55
Max T1 GM (ms)	Resting ABI	19	-0.418	-580.6	0.18	0.13	0.08
	Δ ABI	19	0.507	637.8	0.26	0.21	0.03
	Claudication onset time (sec)	--	--	--	--	--	--
	Peak walking time (sec)	19	0.159	0.939	0.03	-0.03	0.52
	Body mass index (kg/m²)	19	0.485	11.3	0.24	0.19	0.04
	eGFR (ml/min/1.73m²)	18	0.027	0.14	.001	-0.06	0.93

ABI: ankle-brachial index; Δ ABI: difference between resting ABI and post-treadmill walking ABI; eGFR: estimated glomerular filtration rate; ms: milliseconds**.** Maximum T1, the dependent variable tested, corresponding to the maximum measured T1 relaxation time of the referenced anatomic area. AM: Anterior muscle group. LM: Lateral muscle group. DM: Deep muscle group. SM: Soleus muscle. GM: Gastrocnemius muscle.

Table 7b. Association of mean T1 values for muscle compartments in controls with indicated parameters by linear regression.

	Independent Variables	*n*	β	Standard Error	R^2	Adjusted r^2	*p*-value
Mean T1 AM (ms)	Resting ABI	19	-0.036	-27.1	0.001	-0.06	0.88
	Δ ABI	19	0.005	3.43	<0.001	-0.06	0.98
	Claudication onset time (sec)	--	--	--	--	--	--
	Peak walking time (sec)	19	-0.092	-0.296	0.01	-0.05	0.71
	Body mass index (kg/m²)	19	0.182	2.31	0.03	-0.03	0.46
	eGFR (ml/min/1.73m²)	18	-0.109	-0.409	0.01	-0.05	0.67
Mean T1 LM (ms)	Resting ABI	19	-0.256	-225.9	0.07	0.01	0.29
	Δ ABI	19	0.327	261.9	0.11	0.06	0.17
	Claudication onset time (sec)	--	--	--	--	--	--
	Peak walking time (sec)	19	0.022	0.081	<0.001	-0.06	0.93
	Body mass index (kg/m²)	19	-0.154	-2.29	0.02	-0.03	0.53
	eGFR (ml/min/1.73m²)	18	0.112	0.491	0.01	-0.05	0.66
Mean T1 DM (ms)	Resting ABI	19	-0.309	-214.8	0.10	0.04	0.20
	Δ ABI	19	0.427	269.5	0.18	0.14	0.07
	Claudication onset time (sec)	--	--	--	--	--	--
	Peak walking time (sec)	19	-0.108	-0.318	0.01	-0.05	0.66
	Body mass index (kg/m²)	19	0.080	0.935	0.006	-0.05	0.75
	eGFR (ml/min/1.73m²)	18	-0.062	-0.213	0.004	-0.06	0.81
Mean T1 SM (ms)	Resting ABI	19	-0.108	-105.9	0.01	-0.05	0.66
	Δ ABI	19	0.233	206.3	0.05	0.001	0.34
	Claudication onset time (sec)	--	--	--	--	--	--
	Peak walking time (sec)	19	-0.061	-0.253	0.004	-0.06	0.80
	Body mass index (kg/m²)	19	-0.202	-3.33	0.04	-0.02	0.41
	eGFR (ml/min/1.73m²)	18	0.103	0.500	0.01	-0.05	0.68
Mean T1 GM (ms)	Resting ABI	19	-0.091	-106.6	0.01	-0.05	0.71
	Δ ABI	19	0.143	151.5	0.02	-0.04	0.56
	Claudication onset time (sec)	--	--	--	--	--	--
	Peak walking time (sec)	19	-0.035	-0.172	0.001	-0.06	0.89
	Body mass index (kg/m²)	19	0.139	2.73	0.02	-0.04	0.57
	eGFR (ml/min/1.73m²)	18	0.043	0.254	0.002	-0.06	0.86

ABI: ankle-brachial index; Δ ABI: difference between resting ABI and post-treadmill walking ABI; eGFR: estimated glomerular filtration rate**.** AM: Anterior muscle group. LM: Lateral muscle group. DM: Deep muscle group. SM: Soleus muscle. GM: Gastrocnemius muscle.

Table 8a. Association of maximum T1 values for lower extremity arteries in peripheral artery disease patients with indicated parameters by linear regression.

	Independent Variables	*n*	β	Standard Error	R^2	Adjusted r^2	*p*-value
Max T1 AT (ms)	Resting ABI	18	0.009	4.72	0.00	-0.06	0.97
	Δ ABI	17	0.264	171.9	0.07	0.01	0.31
	Claudication onset time (sec)	17	0.333	-0.380	0.11	0.05	0.19
	Peak walking time (sec)	17	0.264	171.9	0.07	0.01	0.31
	Body mass index (kg/m²)	18	0.380	11.30	0.15	0.09	0.12
	eGFR (ml/min/1.73m²)	13	0.075	0.360	0.01	-0.09	0.81
Max T1 PE (ms)	Resting ABI	18	-0.273	-153.0	0.07	0.01	0.31
	Δ ABI	16	0.219	294.1	0.05	-0.02	0.42
	Claudication onset time (sec)	16	-0.117	-0.185	0.01	-0.06	0.67
	Peak walking time (sec)	16	-0.292	-0.454	0.09	0.02	0.27
	Body mass index (kg/m²)	16	0.181	6.20	0.03	-0.04	0.50
	eGFR (ml/min/1.73m²)	12	0.171	0.847	0.03	0.85	0.60
Max T1 PT (ms)	Resting ABI	15	0.139	73.1	0.02	-0.06	0.62
	Δ ABI	14	-0.487	-694.7	0.24	0.17	0.08
	Claudication onset time (sec)	14	-0.645	-0.808	0.42	0.37	0.013
	Peak walking time (sec)	14	-0.306	-0.457	0.29	0.02	0.29
	Body mass index (kg/m²)	15	0.094	3.42	0.01	-0.07	0.74
	eGFR (ml/min/1.73m²)	11	0.379	2.51	0.14	0.05	0.25

AT: Anterior tibial artery. PE: Peroneal artery. PT: Posterior tibial artery. ABI: ankle-brachial index; Δ ABI: difference between resting ABI and post-treadmill walking ABI; eGFR: estimated glomerular filtration rate**.** Maximum T1, the dependent variable tested, corresponding to the maximum measured T1 relaxation time of the referenced anatomic area.

Table 8b. Association of maximum T1 values for lower extremity arteries in pooled cohort (all patients in the study) with indicated parameters by linear regression.

	Independent Variables	*n*	β	Standard Error	R^2	Adjusted r^2	*p*-value
Max T1 AT (ms)	Resting ABI	36	-0.237	-98.1	0.06	0.03	0.16
	Δ ABI	35	0.260	207.0	0.07	0.04	0.13
	Claudication onset time (sec)	35	-0.009	-0.011	<0.001	-0.03	0.96
	Peak walking time (sec)	35	-0.179	-0.298	0.03	0.003	0.30
	Body mass index (kg/m²)	36	0.227	5.53	0.05	0.02	0.18
	eGFR (ml/min/1.73m²)	30	-0.039	-0.217	<0.001	-0.03	0.84
Max T1 PE (ms)	Resting ABI	34	-0.179	-102.0	0.03	0.002	0.31
	Δ ABI	34	0.357	571.7	0.13	0.10	0.038
	Claudication onset time (sec)	34	-0.043	-0.072	0.002	-0.03	0.81
	Peak walking time (sec)	34	-0.148	-0.364	0.02	-0.01	0.40
	Body mass index (kg/m²)	34	-0.046	-1.54	0.002	-0.03	0.80
	eGFR (ml/min/1.73m²)	29	0.286	2.17	0.82	.048	0.13
Max T1 PT (ms)	Resting ABI	30	-0.042	-52.7	0.002	-0.03	0.82
	Δ ABI	29	-0.047	-187.2	0.002	-0.04	0.81
	Claudication onset time (sec)	29	-0.033	-0.137	0.001	-0.04	0.87
	Peak walking time (sec)	29	-0.132	-0.728	0.017	-0.02	0.50
	Body mass index (kg/m²)	30	-0.026	-1.94	0.001	-0.04	0.89
	eGFR (ml/min/1.73m²)	25	-0.042	-0.861	0.002	-0.04	0.84

AT: Anterior tibial artery. PE: Peroneal artery. PT: Posterior tibial artery. ABI: ankle-brachial index; Δ ABI: difference between resting ABI and post-treadmill walking ABI; eGFR: estimated glomerular filtration rate**.** Maximum T1, the dependent variable tested, corresponding to the maximum measured T1 relaxation time of the referenced anatomic area.

Table 8c. Association of maximum T1 values for lower extremity arteries in control subjects with indicated parameters by linear regression. Controls did not experience claudication, therefore no values for this measurement are available.

	Independent Variables	***n***	**β**	**Standard Error**	**R^2**	**Adjusted r^2**	***p*-value**
Max T1 AT (ms)	Resting ABI	18	-0.047	-55.4	0.002	-0.06	0.85
	Δ ABI	18	0.071	89.1	0.005	-0.06	0.78
	Claudication onset time (sec)	--	--	--	--	--	--
	Peak walking time (sec)	18	-0.346	-1.71	0.120	0.07	0.16
	Body mass index (kg/m²)	18	0.071	89.1	0.005	-0.06	0.78
	eGFR (ml/min/1.73m²)	17	-0.021	-0.123	<0.001	-0.07	0.93
Max T1 PE (ms)	Resting ABI	18	-0.062	-121.8	0.004	-0.06	0.81
	Δ ABI	18	0.433	796.1	0.19	0.14	0.07
	Claudication onset time (sec)	--	--	--	--	--	--
	Peak walking time (sec)	18	0.187	1.55	0.04	-0.03	0.46
	Body mass index (kg/m²)	18	-0.129	-4.29	0.02	-0.05	0.61
	eGFR (ml/min/1.73m²)	17	0.383	3.71	0.15	0.09	0.13
Max T1 PT (ms)	Resting ABI	15	0.391	2520.1	0.15	0.09	0.15
	Δ ABI	15	0.022	115.8	<0.001	-0.08	0.94
	Claudication onset time (sec)	--	--	--	--	--	--
	Peak walking time (sec)	15	-0.045	-0.908	0.002	-0.08	0.87
	Body mass index (kg/m²)	15	-0.011	-0.953	<0.001	-0.08	0.97
	eGFR (ml/min/1.73m²)	15	0.391	2520.0	0.02	-0.06	0.65

AT: Anterior tibial artery. PE: Peroneal artery. PT: Posterior tibial artery. ABI: ankle-brachial index; Δ ABI: difference between resting ABI and post-treadmill walking ABI; eGFR: estimated glomerular filtration rate**.** Maximum T1, the dependent variable tested, corresponding to the maximum measured T1 relaxation time of the referenced anatomic area.

Table 9a. Linear regression for mean T1 of the lower extremity arteries with clinical measures (PAD).

	Independent Variables	*n*	β	Standard Error	R^2	Adjusted r^2	*p*-value
Mean T1 AT (ms)	Resting ABI	18	-0.421	-243.0	0.18	0.13	0.08
	Δ ABI	17	0.052	35.3	0.003	-0.06	0.84
	Claudication onset time (sec)	17	-0.100	-0.120	0.01	-0.06	0.70
	Peak walking time (sec)	17	-0.197	-0.276	0.04	-0.03	0.45
	Body mass index (kg/m²)	18	-0.247	-8.07	0.06	0.002	0.32
	eGFR (ml/min/1.73m²)	17	-0.263	-1.07	0.07	0.01	0.31
Mean T1 PE (ms)	Resting ABI	16	-0.139	-79.5	0.02	-0.05	0.61
	Δ ABI	16	-0.033	-45.4	0.001	-0.07	0.90
	Claudication onset time (sec)	16	-0.286	-0.355	0.08	0.02	0.28
	Peak walking time (sec)	16	-0.312	-0.496	0.10	0.03	0.24
	Body mass index (kg/m²)	16	0.022	0.760	0.001	-0.07	0.94
	eGFR (ml/min/1.73m²)	12	0.004	0.020	0.00	-0.10	0.99
Mean T1 PT (ms)	Resting ABI	15	0.157	93.2	0.03	-0.05	0.58
	Δ ABI	14	-0.465	-758.3	0.22	0.15	0.09
	Claudication onset time (sec)	14	-0.472	-0.675	0.22	0.16	0.09
	Peak walking time (sec)	14	-0.046	-0.078	0.002	-0.08	0.88
	Body mass index (kg/m²)	15	-0.036	-1.47	0.001	-0.08	0.90
	eGFR (ml/min/1.73m²)	11	0.217	1.56	0.05	-0.06	0.52

AT: Anterior tibial artery. PE: Peroneal artery. PT: Posterior tibial artery. ABI: ankle-brachial index; Δ ABI: difference between resting ABI and post-treadmill walking ABI; eGFR: estimated glomerular filtration rate.

Table 9b. Linear regression for mean T1 of the lower extremity arteries with clinical measures (controls).

	Independent Variables	*n*	β	Standard Error	R^2	Adjusted r^2	*p*-value
Mean T1 AT (ms)	Resting ABI	18	0.001	0.981	0.00	-0.06	0.99
	Δ ABI	18	-0.159	-140.8	0.03	-0.04	0.53
	Claudication onset time (sec)	N/A					
	Peak walking time (sec)	18	-0.072	-0.249	0.01	-0.06	0.78
	Body mass index (kg/m²)	18	0.163	2.24	0.03	-0.03	0.52
	eGFR (ml/min/1.73m²)	17	-0.263	-1.07	0.07	0.01	0.31
Mean T1 PE (ms)	Resting ABI	16	-0.139	79.5	0.02	-0.05	0.61
	Δ ABI	16	-0.033	-45.4	0.001	-0.07	0.90
	Claudication onset time (sec)	N/A					
	Peak walking time (sec)	18	0.275	1.77	0.075	0.02	0.27
	Body mass index (kg/m²)	18	-0.058	-1.50	0.003	-0.06	0.82
	eGFR (ml/min/1.73m²)	17	0.243	1.83	0.06	0.004	0.35
Mean T1 PT (ms)	Resting ABI	15	0.387	2271.7	0.15	0.08	0.16
	Δ ABI	15	0.012	58.9	<0.001	-0.08	0.97
	Claudication onset time (sec)	N/A					
	Peak walking time (sec)	15	-0.066	-1.22	0.004	-0.07	0.82
	Body mass index (kg/m²)	15	0.041	3.16	0.002	-0.08	0.89
	eGFR (ml/min/1.73m²)	14	-0.162	-4.37	0.026	-0.06	0.58

AT: Anterior tibial artery. PE: Peroneal artery. PT: Posterior tibial artery. ABI: ankle-brachial index; Δ ABI: difference between resting ABI and post-treadmill walking ABI; eGFR: estimated glomerular filtration rate.

Table 9c. Linear regression for mean T1 of the lower extremity arteries with clinical measures (pooled).

	Independent Variables	*n*	β	Standard Error	R^2	Adjusted r^2	*p*-value
Mean T1 AT (ms)	Resting ABI	36	-0.318	-120.0	0.10	0.08	0.06
	Δ ABI	35	0.034	23.6	0.001	-0.03	0.85
	Claudication onset time (sec)	35	<0.001	<0.001	<0.001	-0.03	0.99
	Peak walking time (sec)	35	-0.199	-0.290	0.04	0.01	0.25
	Body mass index (kg/m²)	36	-0.074	-1.65	0.005	-0.02	0.67
	eGFR (ml/min/1.73m²)	30	-0.103	-0.572	0.01	-0.02	0.59
Mean T1 PE (ms)	Resting ABI	34	-0.112	54.8	0.01	-0.02	0.53
	Δ ABI	34	0.163	224.3	0.03	-0.004	0.36
	Claudication onset time (sec)	34	-0.117	-0.171	0.01	-0.02	0.51
	Peak walking time (sec)	34	-0.157	-0.333	0.03	-0.006	0.37
	Body mass index (kg/m²)	34	-0.035	-1.02	0.001	-0.03	0.84
	eGFR (ml/min/1.73m²)	29	0.139	0.860	0.02	-0.02	0.47
Mean T1 PT (ms)	Resting ABI	30	0.001	0.979	<0.001	-0.04	0.99
	Δ ABI	29	-0.074	-272.5	0.005	-0.03	0.70
	Claudication onset time (sec)	29	-0.050	-0.190	0.003	-0.04	0.80
	Peak walking time (sec)	29	-0.066	-0.335	0.004	-0.03	0.74
	Body mass index (kg/m²)	30	0.005	0.347	<0.001	-0.04	0.98
	eGFR (ml/min/1.73m²)	25	-0.076	-1.44	0.006	-0.04	0.72

AT: Anterior tibial artery. PE: Peroneal artery. PT: Posterior tibial artery. ABI: ankle-brachial index; Δ ABI: difference between resting ABI and post-treadmill walking ABI; eGFR: estimated glomerular filtration rate.

Table 10a. Linear regression for lower extremity arteries (composite) with clinical measures (PAD).

	Independent Variables	*n*	β	Standard Error	R^2	Adjusted r^2	*p*-value
Composite T1 (ms)	Resting ABI	18	-0.076	-34.0	0.006	-0.06	0.76
	Δ ABI	17	0.421	220.7	0.18	0.12	0.09
	Claudication onset time (sec)	17	-0.420	-0.387	0.18	0.12	0.09
	Peak walking time (sec)	17	-0.414	-0.414	0.15	0.09	0.13
	Body mass index (kg/m²)	18	0.428	10.8	0.18	0.13	0.08
	eGFR (ml/min/1.73m²)	13	0.257	1.15	0.07	-0.02	0.40

Table 10b. Linear regression for lower extremity arteries (composite) with clinical measures (control).

	Independent Variables	*n*	β	Standard Error	R^2	Adjusted r^2	*p*-value
Composite T1 (ms)	Resting ABI	19	0.208	356.7	0.04	-0.01	0.39
	Δ ABI	19	0.258	401.5	0.07	0.01	0.29
	Claudication onset time (sec)	N/A					
	Peak walking time (sec)	19	-0.030	-0.220	0.001	-0.06	0.90
	Body mass index (kg/m²)	19	0.014	0.393	<0.001	-0.06	0.96
	eGFR (ml/min/1.73m²)	18	0.108	0.923	0.01	-0.05	0.67

Table 10c. Linear regression for lower extremity arteries (composite) with clinical measures (pooled).

	Independent Variables	*n*	β	Standard Error	R^2	Adjusted r^2	*p*-value
Composite T1 (ms)	Resting ABI	37	-0.197	-95.1	0.04	0.01	0.24
	Δ ABI	36	0.337	301.1	0.11	0.09	0.044
	Claudication onset time (sec)	36	-0.009	-0.012	0.00	-0.03	0.96
	Peak walking time (sec)	36	-0.275	-0.525	0.08	0.05	0.10
	Body mass index (kg/m²)	37	0.104	2.97	0.01	-0.02	0.54
	eGFR (ml/min/1.73m²)	31	0.112	0.769	0.01	-0.02	0.55

Composite T1: The representative mean T1 of all three arteries combined rendered as a singular index. ABI: ankle-brachial index; Δ ABI: difference between resting ABI and post-treadmill walking ABI; eGFR: estimated glomerular filtration rate**.**

Table 11a. Linear regression for lower extremity muscle compartments (average T1 of all five muscle groups combined) with clinical measures in peripheral artery disease subjects.

	Independent Variables	*n*	β	Standard Error	R^2	Adjusted r^2	*p*-value
Averaged maximum muscle compartment T1 (ms)	Resting ABI	18	-0.042	-14.5	0.002	-0.06	0.87
	Δ ABI	17	0.043	17.5	0.002	-0.07	0.87
	Claudication onset time (sec)	17	-0.339	-0.241	0.12	0.06	0.18
	Peak walking time (sec)	17	-0.325	-0.270	0.11	0.05	0.20
	Body mass index (kg/m²)	18	0.289	5.57	0.08	0.05	0.20
	eGFR (ml/min/1.73m²)	13	0.232	0.891	0.05	-0.03	0.45

Table 11b. Linear regression for lower extremity muscle compartments (average T1 of all five muscle groups combined) with clinical measures in the control group.

	Independent Variables	*n*	β	Standard Error	R^2	Adjusted r^2	*p*-value
Averaged maximum muscle compartment T1 (ms)	Resting ABI	19	-0.062	-77.0	0.004	-0.06	0.80
	Δ ABI	19	0.461	520.4	0.21	0.17	0.047
	Claudication onset time (sec)	N/A					
	Peak walking time (sec)	19	0.180	0.950	0.03	-0.03	0.46
	Body mass index (kg/m²)	19	0.256	5.37	0.07	0.01	0.29
	eGFR (ml/min/1.73m²)	18	0.011	0.068	0.00	-0.06	0.96

Table 11c. Linear regression for lower extremity muscle compartments (composite) with clinical measures as a pooled analysis encompassing all study participants.

	Independent Variables	*n*	β	Standard Error	R^2	Adjusted r^2	*p*-value
Averaged maximum muscle compartment T1 (ms)	Resting ABI	37	-0.379	-145.1	0.14	0.12	0.021
	Δ ABI	36	0.289	204.3	0.08	0.06	0.09
	Claudication onset time (sec)	36	0.143	0.163	0.02	-0.01	0.40
	Peak walking time (sec)	36	-0.289	-0.436	0.08	0.06	0.09
	Body mass index (kg/m²)	37	0.183	4.14	0.03	0.01	0.28
	eGFR (ml/min/1.73m²)						

ABI: ankle-brachial index; Δ ABI: difference between resting ABI and post-treadmill walking ABI; eGFR: estimated glomerular filtration rate.

Table 12a. Linear regression for lower extremity muscle compartments (mean) with clinical measures in the PAD group.

	Independent Variables	*n*	β	Standard Error	R^2	Adjusted r^2	*p*-value
Mean muscle ECV (%)	Resting ABI	16	-0.056	-1.43	0.003	-0.07	0.84
	Δ ABI	15	-0.003	-0.152	<0.001	-0.08	0.99
	Claudication onset time (sec)	15	0.200	0.011	0.04	-0.03	0.47
	Peak walking time (sec)	15	0.052	0.003	0.003	-0.07	0.85
	Body mass index (kg/m²)	16	-0.191	-0.300	0.04	-0.03	0.48
	eGFR (ml/min/1.73m²)	12	0.106	0.030	0.01	-0.09	0.74

Table 12b. Linear regression for lower extremity arteries (composite) with clinical measures in the control group.

	Independent Variables	*n*	β	Standard Error	R^2	Adjusted r^2	*p*-value
Mean muscle ECV (%)	Resting ABI	12	0.059	4.09	0.003	-0.10	0.86
	Δ ABI	12	0.048	2.62	0.002	-0.10	0.88
	Claudication onset time (sec)	N/A					
	Peak walking time (sec)	12	-0.145	-0.031	0.02	-0.08	0.65
	Body mass index (kg/m²)	12	-0.035	-0.031	0.001	-0.10	0.91
	eGFR (ml/min/1.73m²)	11	0.443	-0.071	0.07	-0.04	0.44

Table 12c. Linear regression for lower extremity arteries (composite) with clinical measures as a pooled analysis of all study participants.

	Independent Variables	*n*	β	Standard Error	R^2	Adjusted r^2	*p*-value
Mean muscle ECV (%)	Resting ABI	28	0.016	0.324	<0.001	-0.04	0.93
	Δ ABI	27	0.019	1.06	<0.001	-0.04	0.93
	Claudication onset time (sec)	27	0.117	0.007	0.01	-0.03	0.56
	Peak walking time (sec)	27	0.014	0.001	<0.001	-0.04	0.95
	Body mass index (kg/m²)	28	-0.091	-0.103	0.008	-0.03	0.65
	eGFR (ml/min/1.73m²)	23	-0.058	-0.016	0.003	-0.04	0.79

ABI: ankle-brachial index; Δ ABI: difference between resting ABI and post-treadmill walking ABI; eGFR: estimated glomerular filtration rate; ECV: extracellular volume fraction.